News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
100% efficacy against severe Covid-19 disease and hospitalizations
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The facility will manufacture its Herceptin biosimilar, Tuznue
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Subscribe To Our Newsletter & Stay Updated
